Intramuscular administration of the iron chelator DFO has been shown to slow cognitive decline in AD patients (282), while high concentrations of MDA and 4-HNE—key lipid peroxidation products—and reduced expression of GPX4 have been detected across multiple brain regions in AD (285). The gene discussed is GPX4; the disease is Alzheimer disease.